List of works - Philippe Rousselot

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

scientific article published in June 2003

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

scientific article published on 27 April 2016

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

scientific article published on 19 May 2016

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

scientific article published on 21 December 2006

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

scientific article published on 02 August 2016

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

scientific article published on 16 April 2012

Discovery of five irregular moons of Neptune

scientific article

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

scientific article

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

scientific article published on 26 June 2013

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

scientific article published on 4 January 2005

Frequent antibody production against RARalpha in both APL mice and patients

scientific article published on 25 May 2006

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

scientific article

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

scientific article published on 13 October 2015

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

scientific article

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

scientific article

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

scientific article published on 25 February 2014

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

scientific article

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

scientific article published on 29 November 2011

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

scientific article

OSSOS. IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune ⬇️

scientific article published in Astronomical Journal

OSSOS. VII. 800+ Trans-Neptunian Objects—The Complete Data Release

scientific article

OSSOS. XI. No active centaurs in the Outer Solar System Origins Survey

scientific article

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

scientific article

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

scientific article

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

scientific article published on 10 June 2013

Pulmonary Complications of Bcr-Abl Tyrosine Kinase Inhibitors

scientific article published on 11 June 2020

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

scientific article

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

scientific article published on 4 January 2010

The outer solar system origins survey. I. Design and first-quarter discoveries ⬇️

scientific article published in Astronomical Journal

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

scientific article

List of works by Philippe Rousselot

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Discovery of five irregular moons of Neptune

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

Frequent antibody production against RARalpha in both APL mice and patients

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

OSSOS. IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune ⬇️

OSSOS. VII. 800+ Trans-Neptunian Objects—The Complete Data Release

OSSOS. XI. No active centaurs in the Outer Solar System Origins Survey

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

Pulmonary Complications of Bcr-Abl Tyrosine Kinase Inhibitors

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

The outer solar system origins survey. I. Design and first-quarter discoveries ⬇️

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).